
    
      Clinical trial for the safety and efficacy of Non-viral programmed cell death protein-1(PD1)
      integrated anti-prostate-specific-membrane-antigen(PSMA) chimeric antigen receptor T(CART)
      cells in the treatment of Refractory Castrate-Resistant Prostate Cancer(CRPC)
    
  